Table 5.
Immune modifiers and other non-specific drugs for HCV and phase of clinical trials (phases 2 and 3)
| Drug | Company | Phase |
|---|---|---|
| Interferon | ||
| Albuferon (interferon/albumin fusion) | Human Genome Sciences | 3 |
| Omega interferon | Intarcia | 2 |
| Lactoferon | Biolex/OctoPlus | 2 |
| IET | Transition Therapeutics | 2 |
| Others | ||
| Zadaxin: thymalphasin | SciClone Pharma/Sigmatau | 3 |
| SCV-07 | SciClone Pharma | 2 |
| MX3235 | Migenix | 2 |
| Civacir | NABI | 2 |
| Suvus | Bioenvision | 2 |
| Alinia (nitazoxanide: NTZ) | Romark Laboratories | 2 |
| KPE02003002 | Kemin Pharma | 2 |
| Lenocta (sodium stibogluconate SSG) | VioQuest Pharmaceuticals | 2 |
| CTS-1027 MMP inhibitor | Conatus | 2 |
| JKB-122 | Jerkin | 2 |
| Fluvastatin | Oklahoma University HSC | 2 |
| Mito-Q | Antipodean | 2 |
| PYN17 | Phynova | 2 |
| CB5300 | Canopus | 2 |
| CF102 | Can-Fite | 2 |
| Debio 025 | Debiopharm | 2 |
| CYT107 | Cytheris | 2 |
Reference: Hepatitis C new drug pipeline (http://www.hcvdrugs.com, accessed on 2/9/2010)